% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Catanzaro:180368,
      author       = {G. Catanzaro and Z. M. Besharat and A. Carai and N.
                      Jäger$^*$ and E. Splendiani and C. Colin and A. Po and M.
                      Chiacchiarini and A. Citarella and F. Gianno and A.
                      Cacchione and E. Miele and F. Diomedi Camassei and M. Gessi
                      and L. Massimi and F. Locatelli and D. Jones$^*$ and D.
                      Figarella-Branger and S. Pfister$^*$ and A. Mastronuzzi and
                      F. Giangaspero and E. Ferretti},
      title        = {{M}i{R}-1248: a new prognostic biomarker able to identify
                      supratentorial hemispheric pediatric low-grade gliomas
                      patients associated with progression.},
      journal      = {Biomarker Research},
      volume       = {10},
      number       = {1},
      issn         = {2050-7771},
      address      = {London},
      publisher    = {Biomed Central},
      reportid     = {DKFZ-2022-01282},
      pages        = {44},
      year         = {2022},
      abstract     = {Pediatric low-grade gliomas (pLGGs), particularly
                      incompletely resected supratentorial tumours, can undergo
                      progression after surgery. However to date, there are no
                      predictive biomarkers for progression. Here, we aimed to
                      identify pLGG-specific microRNA signatures and evaluate
                      their value as a prognostic tool.We identified and validated
                      supratentorial incompletey resected pLGG-specific microRNAs
                      in independent cohorts from four European Pediatric
                      Neuro-Oncology Centres.These microRNAs demonstrated high
                      accuracy in differentiating patients with or without
                      progression. Specifically, incompletely resected
                      supratentorial pLGGs with disease progression showed
                      significantly higher miR-1248 combined with lower
                      miR-376a-3p and miR-888-5p levels than tumours without
                      progression. A significant (p < 0.001) prognostic
                      performance for miR-1248 was reported with an area under the
                      curve (AUC) of 1.00. We also highlighted a critical
                      oncogenic role for miR-1248 in gliomas tumours. Indeed, high
                      miR-1248 levels maintain low its validated target genes
                      (CDKN1A (p21)/FRK/SPOP/VHL/MTAP) and consequently sustain
                      the activation of oncogenic pathways.Altogether, we provide
                      a novel molecular biomarker able to successfully identify
                      pLGG patients associated with disease progression that could
                      support the clinicians in the decision-making strategy,
                      advancing personalized medicine.},
      keywords     = {Pediatric low-grade gliomas (Other) / Personalized medicine
                      (Other) / Prognostic biomarker (Other) / Risk stratification
                      (Other) / Tumour progression (Other) / miR-1248 (Other)},
      cin          = {B062 / HD01 / B360},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)B360-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35715818},
      doi          = {10.1186/s40364-022-00389-x},
      url          = {https://inrepo02.dkfz.de/record/180368},
}